Pharmaceutical Outsourcing

Published on: 04/07/2015

M&A activity in the pharmaceutical outsourcing industry accelerated in 2014, with 92 transactions recorded for the year, a substantial increase over prior years’ figures. The industry’s robust activity is reflective of positive market trends, including a growing Big Pharma pipeline and their increased use of contract services. Meanwhile, pharmaceutical manufacturers are demanding more and more services from fewer and fewer vendors, leading to intensified consolidation in the industry as vendors work to add capabilities to meet this demand. At the same time, M&A market fundamentals remain favorable, underpinned by low interest rates, readily available financing, strong cash positions among corporate buyers, and an abundance of undeployed private equity capital.

Key Contacts